descriptive
Analysis v1
32
0
For people who had a liver transplant and have fatty liver disease, taking saroglitazar for 24 weeks lowered the amount of fat in their liver from about 10% to 8% on average. This finding is from the abstract summary - full study details were not available
Scientific Claim
In liver transplant recipients with NAFLD, treatment with saroglitazar 4 mg daily for 24 weeks was associated with a reduction in liver fat (MRI-PDFF) from 10.3% to 8.1% on average.
Original Statement
“Saroglitazar treatment led to a reduction in MRI-PDFF from 10.3±10.5% at baseline to 8.1±7.6%.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is single-arm with no control group, so it can only show association, not causation. The phrase 'led to' overstates the findings.
Evidence from Studies
Supporting (1)
32
32
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
Cross-Sectional Study
Human
2023 Sep 1Contradicting (0)
0
No contradicting evidence found